Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat

Anna Shin(Seoul National University Bundang Hospital), Eun Ha Kang(Seoul National University Bundang Hospital), Yun Jong Lee(Seoul National University), You‐Jung Ha(Seoul National University Bundang Hospital), Minji Han(Seoul National University Bundang Hospital), Se Rim Choi(Hanyang University Seoul Hospital), Eun Bong Lee(Seoul National University Hospital)
Seminars in Arthritis and Rheumatism
August 3, 2022
10.1016/j.semarthrit.2022.152080
Cited by 10

Related Papers

Prevalence of Comorbidity among People with Hypertension: The Korea National Health and Nutrition Examination Survey 2007-2013
|Korean Circulation Journal|2016|92
Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout
|European Heart Journal|2021|75
Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study
|BMJ|2024|55
Weight perception and its association with socio-demographic and health-related factors among Korean adolescents
|BMC Public Health|2015|53
Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study
|Lara D. Veeken|2019|36